Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers, the Trump administration said Tuesday.
The drugs selected include some of the medications on which Medicare spends the most money. That means the deals negotiated this year have the potential to deliver significant savings to taxpayers when they go into effect in 2028.
